Novo Investors Seek Clarity on Wegovy Weight-Loss Drug Shortages
When Novo Nordisk publishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease.
Reuters Health Information
source https://www.medscape.com/s/viewarticle/997802?src=rss
Reuters Health Information
source https://www.medscape.com/s/viewarticle/997802?src=rss
Comments
Post a Comment